BLOG / 🇺🇸 United States / ipo capital markets · · daily

US IPO Pipeline SEC S-1 Filings — June 26, 2026

IPO Pipeline

By Gunpowder Editorial ·

5 high priority 5 total filings analysed

Executive Summary

The June 26, 2026 SEC filings reveal a bifurcated IPO/pipeline landscape with three distinct themes: a wave of speculative, high-risk SPAC and micro-cap capital raises targeting digital assets and penny-stock restructuring; a traditional, accretive regional bank merger in the financial sector; and a clinical-stage biotech struggling to stay afloat.

Three of the five filers (Professional Diversity Network, Coeptis Therapeutics, and Jupiter Neurosciences) share a common pattern of deep financial distress, with going-concern warnings, chronic net losses, and pivots into unproven or highly volatile asset classes like cryptocurrency mining and tokenization. Meanwhile, AMR Resources Acquisition Corp. represents a blank-check vehicle raising $250M, providing a conduit for private mineral-resource companies to go public, but carries high pre-deal uncertainty. In contrast, Hawthorn Bancshares' bank merger demonstrates tangible pro forma EPS accretion (+2.3% to $3.52) and a clear, cost-synergy-driven integration plan within a stable regulatory framework. The most critical takeaway is that insider activity is absent across all deals, and forward-looking guidance is either nonexistent or heavily caveated, forcing investors to rely on disclosed breakeven thresholds (e.g., Dogecoin price targets) and high-burn-rate timelines as the primary valuation anchors.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: S-1

Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from June 18, 2026.

Investment Signals (8)

  • Hawthorn Bancshares (HWBK) (BULLISH)
    ▲

    Pro forma EPS accretion of +2.3% ($3.52 vs $3.44 standalone), combined assets of $2.23B, and only $3.8M in estimated merger costs (net of tax) signal a disciplined, immediately accretive bank merger with limited integration risk

  • Coeptis Therapeutics (COEP) (BEARISH)
    ▲

    Dogecoin breakeven price estimated at $0.13–$0.15/DOGE vs. recent trading of $0.085/DOGE (48–76% below breakeven), combined with $113.9M accumulated deficit and no revenue, makes the business model unsustainable absent a sharp DOGE rally

  • Jupiter Neurosciences (JUNS) (BEARISH)
    ▲

    Yorkville standby equity purchase agreement (SEPA) for 16M shares provides a liquidity backstop but creates persistent overhang and dilution risk, given zero revenue from drugs and a going-concern opinion

  • Professional Diversity Network (PDN) (BEARISH)
    ▲

    Pivot into musical copyright and RWA tokenization is a radical departure from a failing recruitment business; the unit offering structure ($0.6364/unit) and seven-year straggling history of losses make this a high-risk special situation with no margin of safety

  • AMR Resources Acquisition Corp. (AMRR) ↓
    ▲

    13 non-managing institutional investors expressing non-binding interest to buy up to 11.35M units (45% of offering) provides a partial demand signal; however, no target yet selected, and warrants at $11.50 strike offer upside optionality only if a high-quality mineral deal emerges [BULLISH for SPAC arbitrageurs, NEUTRAL for long-term holders]

  • Hawthorn Bancshares (HWBK) (MIXED)
    ▲

    Pro forma net interest margin (NIM) and cost-of-deposit data were not disclosed, but the merger is expected to add $2.2M in non-interest expense, partially offsetting synergies—investors should monitor expense creep

  • Jupiter Neurosciences (JUNS) (SPECULATIVE BULLISH)
    ▲

    Phase IIa Parkinson's trial (IND approved Nov 2025) expected to start Q2 2026 with 12-month readout; Nugevia supplement shipments began Q4 2025 (direct-to-consumer) but remain immaterial; binary catalyst with high optionality for high-risk appetite

  • Professional Diversity Network (PDN)
    ▲

    Pre-funded warrants at $0.01/share offering a 98.4% discount to the unit price create an immediate arbitrage for institutional buyers but dilute common shareholders significantly [BEARISH for retail]

Risk Flags (7)

  • Coeptis Therapeutics / Going Concern & Asset Impairment↓ [HIGH RISK]
    ▼

    Accumulated deficit of $113.9M as of Mar 31, 2026, and Dogecoin price ($0.085/DOGE) 35% below the low-end breakeven ($0.13/DOGE) puts the entire $660.3M ASIC miner fleet at risk of impairment; no revenue from mining yet disclosed

  • Jupiter Neurosciences / SEC Dilution Overhang↓ [HIGH RISK]
    ▼

    Registration of 16M shares (unknown % of diluted float) for Yorkville under SEPA, combined with a going-concern opinion for both FY2024 and FY2025, signals that the company is funding operations exclusively via equity line, which is a classic value-destructive trap

  • Professional Diversity Network / Business Model Failure↓ [HIGH RISK]
    ▼

    The filing admits the legacy recruitment business faces “significant headwinds,” and the company has a consistent history of operating losses with no timeline to profitability; the pivot into tokenization/RWA copyrights has zero disclosed track record or assets under management

  • AMR Resources / Blind Pool Risk↓ [MEDIUM RISK]
    ▼

    No specific target identified, and the 13 institutional expressions of interest are non-binding; if a deal fails to close, the SPAC must liquidate with ~$10.00/share, limiting upside and offering only a risk-free return for early redeemers

  • Coeptis Therapeutics / Lock-Up Restriction Trap↓ [MEDIUM RISK]
    ▼

    Shares distributed via BSG can only be sold if VWAP > $16.00 for 10 days (vs. current no-trade reference), with a monthly cap of 1/18th; this severely restricts selling pressure in the short term but creates a sharp cliff if the price ever spikes

  • Hawthorn Bancshares / Merger Cost Overrun↓ [LOW-MEDIUM RISK]
    ▼

    $3.8M in estimated merger costs (net of $0.8M taxes) plus $2.2M in additional non-interest expense for FY2025 could expand if integration hits snags; the pro forma P&L shows only partial offset to accretion

  • All Five Filers / Insider Activity Absence (COMMON RED FLAG)
    ▼

    None of the five filings report insider buying or selling activity. In the context of an IPO pipeline, the absence of insider participation (especially at Coeptis, PDN, and Jupiter) signals low conviction from management in their own valuations

Opportunities (6)

  • Hawthorn Bancshares (HWBK) / Accretive Bank Merger (OPPORTUNITY)
    ◆

    Pro forma EPS of $3.52 vs. standalone $3.44 (+2.3%), combined with total deposits of $1.86B and a low-cost core deposit base ($490.4M non-interest bearing), offers a classic roll-up value play; anticipate further consolidation in the small-cap banking space

  • AMR Resources Acquisition Corp. (AMRR) / Mineral-Sector SPAC Arbitrage↓ (OPPORTUNITY)
    ◆

    At $10/unit with a 2:1 warrant sweetener (assuming typical structure), the risk/reward favors early investors if management can secure a mineral asset deal with hard assets (e.g., lithium, rare earths); tracking the 13 institutional investors’ final participation is key

  • Jupiter Neurosciences (JUNS) / Parkinson's Phase IIa Catalyst (SPECULATIVE OPPORTUNITY)
    ◆

    With IND approval granted Nov 2025, trial initiation in Q2 2026, and a 12-month readout expected by mid-2027, there is a binary catalyst on a stock heavily beaten down; watch for insider buying ahead of results as a confirming signal

  • Professional Diversity Network (PDN) / RWA Tokenization Play (SPECULATIVE OPPORTUNITY)
    ◆

    If the pivot into tokenizing musical copyrights and other real-world assets gains traction, PDN could ride the growing institutional interest in on-chain asset tokenization; however, the lack of any initial portfolio makes this a lottery ticket

  • Coeptis Therapeutics (COEP) / Short-Squeeze Potential (SPECULATIVE OPPORTUNITY)
    ◆

    With a tiny float (100k shares registered for resale vs. large short interest potential), lock-up restrictions that prevent selling below $16, and a volatility-friendly crypto theme, COEP could be susceptible to a short-squeeze if Dogecoin rallies to $0.13–$0.15

  • Hawthorn Bancshares (HWBK) / Relative Value vs. Regional Bank Peers (OPPORTUNITY)
    ◆

    Pro forma P/E of ~6.3x (based on $3.52 EPS and a rough stock price estimate from the S-4) is cheap versus the regional bank average of ~10x; the merger reduces cost-of-funds pressure and diversifies loan book

Sector Themes (5)

  • Distressed Micro-Caps Pivoting into Crypto/Tokenization
    ◆

    2 out of 5 filers (Coeptis and Professional Diversity Network) are explicitly abandoning legacy businesses (biopharma, recruitment) to pursue cryptocurrency mining and RWA tokenization. This reflects a pattern of desperation fundraises where legacy operations are no longer viable, and companies are chasing speculative narratives to attract retail capital.

  • Blank-Check IPOs Return to Resource Sectors
    ◆

    AMR Resources (mineral focus) marks a continuation of theme-specific SPACs targeting hard assets. Unlike the 2021 craze, these SPACs have lower valuations, more stringent warrants (11.50 strike), and a focus on cash-flow positive natural resource assets—suggesting a more disciplined SPAC market.

  • Bank M&A on the Rise with Measured Synergies
    ◆

    Hawthorn’s S-4 is part of a broader trend in small-cap bank consolidation to combat margin compression. The pro forma accretion (+2.3%) offsets only $3.8M in costs, indicating that the market is pricing in execution risk; still, such deals often provide a floor for stock prices during regulatory review.

  • Clinical-Stage Biotech Funding via Equity Lines
    ◆

    Jupiter Neurosciences’ reliance on a Yorkville SEPA—rather than dilutive offerings or partnerships—shows that early-stage biotech firms without a revenue story are turning to structured equity lines as a last resort, often leading to severe dilution and negative stock momentum.

  • Insider Activity Devoid Across IPO Pipeline
    ◆

    None of the five filings disclosed any insider transactions (buy/sell). In the context of IPOs and follow-ons, the total absence of insider purchases—especially at the offer price—is a significant bearish signal indicating that management does not have sufficient confidence to participate alongside public investors.

Watch List (6)

  • Coeptis Therapeutics (COEP) (CONSTANT)
    👁

    Dogecoin price vs. $0.13 breakeven threshold; monitor any mining revenue disclosures in a Form 10-Q; watch for lock-up expiration or any insider selling after the restriction period

  • Jupiter Neurosciences (JUNS) (CONSTANT)
    👁

    Phase IIa Parkinson's trial patient enrollment start (expected Q2 2026) and subsequent milestone updates; Yorkville share resale activity—if Yorkville immediately offloads shares, it's a bearish signal

  • AMR Resources Acquisition Corp. (AMRR)↓
    👁

    Deadline to announce a target (within 12 months of IPO per standard SPAC rules); watch for any 13D filings from the 13 institutional investors showing actual purchases vs. non-binding interest [12 MONTHS FROM IPO]

  • Hawthorn Bancshares (HWBK)
    👁

    Shareholder vote on the merger and regulatory approvals from the Fed and OCC; pro forma performance in the first quarter post-close (expense synergy realization) [VOTE: TBD; CLOSE: H2 2026]

  • Professional Diversity Network (PDN) (WEEKS TO MONTHS)
    👁

    Effectiveness date of the S-1; first disclosure of RWA tokenization asset acquisitions; any insider buying at the $0.6364 offering price as a sign of conviction

  • All Filings
    👁

    Track any amendments (S-1/A, S-4/A) that include updated pricing, financial projections, or insider activity; the first amendment often reveals the real offering size and management’s commitment [NEXT 30 DAYS]

Filing Analyses (5)
Professional Diversity Network, Inc. S-1 mixed materiality 8/10

26-06-2026

Professional Diversity Network, Inc. filed an S-1 registration statement on June 26, 2026, for a public offering of up to 15,713,387 Units at an assumed price of $0.6364 per Unit, each consisting of one share of Common Stock and one Warrant. The company is also offering Pre-Funded Units to avoid exceeding beneficial ownership limits. Proceeds will support a strategic pivot into new, unrelated business areas including the acquisition of musical copyrights and tokenization of Real World Assets, while the company acknowledges it has a history of operating losses and that its legacy recruitment business faces significant headwinds.

  • · The Warrants expire three years from issuance and have an exercise price equal to 100% of the public offering price per Unit ($0.6364).
  • · Pre-Funded Warrants are exercisable immediately at $0.01 per share and may be exercised on a cashless basis.
  • · Principal executive office is at 55 E. Monroe Street, Suite 2120, Chicago, Illinois.
  • · The company was originally an Illinois LLC in 2003 and went through several name changes before its IPO in 2013.
  • · Colorful Japan, a wholly owned subsidiary in Tokyo, was established in 2025 but is not yet a material contributor to revenues.
  • · The company acknowledges significant headwinds in its traditional recruitment business and a lack of operational history in the newly targeted business areas.
JUPITER NEUROSCIENCES, INC. S-1 mixed materiality 8/10

26-06-2026

Jupiter Neurosciences, Inc. filed an S-1 registration statement to register an additional 16,000,000 shares for resale by Yorkville under a Standby Equity Purchase Agreement (SEPA). The company is a clinical-stage pharmaceutical firm developing JOTROL™ for CNS disorders and has launched a consumer supplement line, Nugevia. However, the company has not generated meaningful revenue from product sales, has incurred significant net losses since inception, and its auditor has expressed substantial doubt about its ability to continue as a going concern.

  • · The company's auditor included an explanatory paragraph regarding going concern in audit reports for fiscal years ended December 31, 2025 and 2024.
  • · The Phase IIa clinical trial for Parkinson's Disease received final IND approval by the FDA in November 2025, expected to start in Q2 2026 with results anticipated 12 months later.
  • · Nugevia product shipments began in Q4 2025 through a direct-to-consumer model.
  • · The company has entered service agreements with firms in Hong Kong and an agreement with Dominant Treasure Health for business development in China, Malaysia, and Singapore.
  • · The company faces risk of delisting from The Nasdaq Capital Market if it fails to meet continued listing requirements.
Coeptis Therapeutics Holdings, Inc. S-1 negative materiality 9/10

26-06-2026

Coeptis Therapeutics Holdings, Inc. filed an S-1 registration statement on June 26, 2026, registering up to 100,000 shares of Common Stock (0.19% of outstanding) for resale by a selling securityholder following its April 2026 business combination with Z Squared Inc. The company transitioned from biopharmaceuticals to digital asset mining, acquiring a fleet of 9,800 ASIC miners valued at $660.3M. However, the company faces substantial going concern risk with an accumulated deficit of $113.9M as of March 31, 2026, and its primary cryptocurrency, Dogecoin, was trading at $0.085 per DOGE as of June 8, 2026—below its estimated breakeven price of $0.13–$0.15 per DOGE, threatening operational viability.

  • · Lock-up restrictions on BSG-distributed shares: no sales unless VWAP > $16.00 over 10 trading days; monthly cap of 1/18th of shares; sales ≤5% of 10-day average daily volume; no short sales; restrictions terminate if closing price > $35.00 for two consecutive days.
  • · Hosting power cost under MSA with Minting Dome: $0.088 per kWh.
  • · Breakeven DOGE price: ~$0.13 per DOGE (with LTC credit) and ~$0.15 per DOGE on a DOGE-only basis.
  • · OpCo was incorporated in December 2022 and had not commenced principal operations or generated revenue prior to the Business Combination.
  • · The fleet consists predominantly of overclocked L7 units, not L9 units assumed in the $660.3M valuation.
  • · GEAR Therapeutics retained; Coeptis issued 1,000,000 shares to CHI and granted CHI an option to acquire GEAR at fair market value, exercisable from October 24, 2026 for 24 months.
  • · Common stock trades on Nasdaq Global Market under symbol 'ZSQR'.
AMR Resources Acquisition Corp. S-1 neutral materiality 8/10

26-06-2026

AMR Resources Acquisition Corp., a Cayman Islands blank check company, filed an S-1 registration statement on June 26, 2026, for an initial public offering of 25,000,000 units at $10.00 per unit, targeting $250,000,000 in proceeds. The company intends to focus on target businesses in the mineral resources sector but may pursue any industry. The sponsor and BTIG have committed to purchase 687,500 private units, and 13 non-managing institutional investors have expressed interest in purchasing up to 11,350,000 units. However, the company has not yet selected any business combination target, and the expressions of interest are non-binding, creating inherent uncertainty.

  • · Warrants have an exercise price of $11.50 per share and become exercisable 30 days after the initial business combination, expiring five years after.
  • · 13 non-managing institutional investors have expressed interest (non-binding) in purchasing up to ~11,350,000 units in the offering (assuming full over-allotment).
  • · The company expects to focus on mineral resources sector target businesses but may pursue any business, industry, sector or geographical location.
  • · No substantive discussions with any business combination target have been initiated as of filing date.
  • · Redemption rights for public shareholders are available upon business combination, with a limitation of 15% of shares sold in the offering for redemption by any single shareholder if a shareholder vote is held (without prior consent).
  • · The sponsor purchased 7,666,667 Class B ordinary shares for $25,000 on December 26, 2025, and an additional 1,916,666 founder shares on June 17, 2026 for no consideration.
  • · Private units sold to sponsor and BTIG are identical to public units; non-managing sponsor investors will purchase private units indirectly through non-managing sponsor membership interests.
  • · Underwriters have a 45-day option to purchase up to an additional 3,750,000 units for over-allotments.
HAWTHORN BANCSHARES, INC. S-4 positive materiality 8/10

26-06-2026

Hawthorn Bancshares, Inc. (HWBK) filed an S-4 registration statement with the SEC on June 26, 2026, in connection with its merger with FBI (First Bancshares, Inc.). The pro forma combined entity would have total assets of $2.23B and total deposits of $1.86B as of March 31, 2026. Pro forma net income for FY2025 is $25.8M (basic EPS $3.52), up from HBI standalone net income of $23.8M (basic EPS $3.44), reflecting accretion from the transaction. However, the merger is expected to incur $3.8M in estimated merger costs (net of $0.8M taxes), and the pro forma adjustments include $2.2M in additional non-interest expense for FY2025, partially offsetting the benefits.

  • · Pro forma total assets of $2.23B as of March 31, 2026, up from HBI standalone $1.86B and FBI $383.8M.
  • · Pro forma total deposits of $1.86B as of March 31, 2026, with $490.4M non-interest bearing and $1.37B interest-bearing.
  • · Pro forma net loans of $1.71B as of March 31, 2026, with allowance for credit losses of $22.8M.
  • · Pro forma goodwill of $16.1M and core deposit intangible of $7.6M recorded as of March 31, 2026.
  • · Pro forma net interest income for FY2025 was $79.7M, up from HBI standalone $65.9M and FBI $12.8M.
  • · Pro forma non-interest expense for FY2025 was $63.5M, including $2.2M in acquisition-related adjustments.
  • · Estimated merger costs of $3.8M (net of $0.8M taxes) are excluded from pro forma financials and will be recognized over time.
  • · Pro forma basic EPS for FY2025 was $3.52, compared to HBI standalone $3.44, representing ~2.3% accretion.
  • · Pro forma basic EPS for Q1 2026 was $0.88, compared to HBI standalone $0.83, representing ~6.0% accretion.

Get daily alerts with 8 investment signals, 7 risk alerts, 6 opportunities and full AI analysis of all 5 filings

Start free trial Browse all digests

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US IPO Pipeline SEC S-1 Filings

June 16, 2026

US IPO Pipeline SEC S-1 Filings — June 16, 2026

June 15, 2026

US IPO Pipeline SEC S-1 Filings — June 15, 2026

June 12, 2026

US IPO Pipeline SEC S-1 Filings — June 12, 2026

June 11, 2026

US IPO Pipeline SEC S-1 Filings — June 11, 2026

🇺🇸 More from United States

View all →

June 19, 2026

US Pre-Market SEC Filings Roundup — June 19, 2026

US Pre-Market SEC Filings Roundup

June 19, 2026

Global High-Priority Regulatory Events — June 19, 2026

Global High-Priority Regulatory Events

June 18, 2026

US Pre-Market SEC Filings Roundup — June 18, 2026

US Pre-Market SEC Filings Roundup

June 18, 2026

US SEC Trading Suspension Halt Orders — June 18, 2026

US SEC Trading Suspension Halt Orders
← All United States digests